Related Experiment Videos
Development of novel telomerase inhibitors based on a bisindole unit
1Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. sasaki@phar.kyushu-u.ac.jp
Abstract:
Telomerase is the enzyme that elongates telomere repeat at the ends of a chromosome. As high telomerase activity is observed in most cancer cells, inhibitors of human telomerase have been expected as new chemotherapeutic agents for cancer. We describe here the discovery of novel inhibitors with IC50 values in the submicromolar range. The structure of the novel inhibitors will be useful as a scaffold for construction of the library in the search for telomerase inhibitors.
Insights
Researchers discovered novel inhibitors targeting telomerase, an enzyme crucial for cancer cell survival. These compounds, with submicromolar IC50 values, offer a promising scaffold for developing new cancer therapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Telomerase is essential for maintaining telomere length at chromosome ends.
- Elevated telomerase activity is a hallmark of most human cancers.
- Targeting telomerase presents a promising strategy for cancer chemotherapy.
Purpose of the Study:
- To discover and characterize novel inhibitors of human telomerase.
- To evaluate the potential of these inhibitors as anti-cancer agents.
Main Methods:
- Enzyme inhibition assays to determine IC50 values.
- Chemical synthesis of novel inhibitor structures.
- Structure-activity relationship analysis.
Main Results:
- Discovery of novel telomerase inhibitors with IC50 values in the submicromolar range.
- Identification of a promising structural scaffold for further inhibitor development.
Conclusions:
- Novel inhibitors demonstrate potent telomerase inhibition.
- The identified scaffold is valuable for designing new libraries of telomerase inhibitors for cancer therapy.